Skip to main content
Hualan Biological Vaccine Inc. logo

Hualan Biological Vaccine Inc. — Investor Relations & Filings

Ticker · 301207 ISIN · CNE1000058J9 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 450 across all filing types
Latest filing 2026-03-27 Governance Information
Country CN China
Listing Shenzhen Stock Exchange 301207

About Hualan Biological Vaccine Inc.

https://www.hualanbacterin.com

Hualan Biological Vaccine Inc. is a specialized enterprise focused on the research, development, production, and distribution of human vaccines. The company is recognized for its extensive portfolio of influenza vaccines, including quadrivalent and trivalent split virus formulations, and was the first globally to develop the H1N1 pandemic influenza vaccine. Its product range also encompasses recombinant hepatitis B vaccines, meningococcal polysaccharide vaccines, and other critical immunizations. Utilizing advanced research and development platforms and large-scale manufacturing facilities, the company adheres to rigorous quality management standards to ensure the safety and efficacy of its biological products. By prioritizing technological innovation and production scalability, the firm addresses diverse public health requirements and maintains a significant role in both routine immunization schedules and emergency pandemic response efforts.

Recent filings

Filing Released Lang Actions
关于修订《公司章程》及其附件的公告
Governance Information Classification · 95% confidence The document is an announcement regarding the revision of the company's Articles of Association (公司章程) and related attachments, specifically about adjusting the number of board members. It includes details about board structure changes and references to legal compliance and governance. There is no financial data, no mention of annual or quarterly reports, no voting results, and no mention of a meeting or shareholder vote results. The document is a formal announcement about governance changes, specifically board composition and company bylaws. This fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2026-03-27 Chinese
独立董事提名人声明与承诺（章金刚）
Board/Management Information Classification · 95% confidence The document is a formal statement and commitment regarding the nomination of an independent director candidate for the company's board. It includes detailed declarations about the nominee's qualifications, compliance with regulatory requirements, and independence criteria. There are no financial statements, earnings data, or report summaries. The content is focused on board/management information, specifically about a nomination for a board position. The document length is 4450 characters, which is relatively short and consistent with a nomination statement rather than a full report. Therefore, the document fits best under the category of Board/Management Information (MANG).
2026-03-27 Chinese
独立董事候选人声明与承诺（张守涛）
Board/Management Information Classification · 100% confidence The document is a detailed declaration and commitment statement by an independent director candidate for a company's board. It includes statements about qualifications, compliance with laws and regulations, and commitments related to the role of an independent director. There is no financial data, no report of financial results, no voting results, no announcement of a meeting, no legal proceedings, no capital changes, and no other financial or regulatory filings. This document is related to board/management information, specifically about a candidate for the board of directors. Therefore, the appropriate classification is Board/Management Information (MANG). The document length is 4709 characters, which is sufficient for a full statement rather than a brief announcement.
2026-03-27 Chinese
关于董事会换届选举的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the re-election and nomination of the company's board of directors, including details about the candidates, their qualifications, and the process for the upcoming board term. It discusses changes in the board composition, candidate biographies, and compliance with relevant laws and regulations. There is no financial data, earnings information, or report publication mentioned. The content is focused on board/management changes and governance matters. Therefore, the document fits the category of Board/Management Information (MANG). The document length is 4534 characters, which is sufficient for a detailed announcement but not a full report.
2026-03-27 Chinese
关于使用自有资金进行委托理财的公告
Capital/Financing Update Classification · 90% confidence The document is an announcement by 华兰生物疫苗股份有限公司 regarding the use of its own funds for entrusted financial management. It details the investment plan, approval procedures, risk control measures, and independent directors' opinions. The document is relatively short (1471 characters) and does not contain financial statements or detailed financial data. It is an update on financing activities related to the company's capital management but does not report on fundraising or capital structure changes like a financing update would. Instead, it is a formal announcement about the company's decision and approval to use funds for financial investment purposes. This fits best under Capital/Financing Update (CAP) as it relates to the company's use of capital for financial management purposes.
2026-03-27 Chinese
会计师事务所选聘制度（2026年3月）
Governance Information Classification · 95% confidence The document is titled '会计师事务所选聘制度' which translates to 'Accounting Firm Selection System'. It details the procedures, requirements, and governance related to the selection, appointment, and replacement of the company's external auditors (accounting firms). It references relevant laws, regulatory bodies such as the China Securities Regulatory Commission, and internal company governance rules. The document is a policy or procedural manual rather than a financial report, audit report, or announcement. It does not contain financial statements, audit opinions, or results but rather outlines the internal control and governance framework for auditor selection. Therefore, it is not an Annual Report (10-K), Audit Report (AR), or any financial report. It is also not a simple announcement or certification. The content fits best under Governance Information (CGR), as it details internal rules and governance practices related to auditor selection and oversight.
2026-03-27 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.